In-vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and β-haemolytic streptococci

Journal of Antimicrobial Chemotherapy

Volumn 44, Issue 4, 1999, Pages 445-453

  Wootton, M ^a   Bowker, K E ^a   Janowska, A ^a   Holt, H A ^a   MacGowan, A P ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFOTAXIME; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; PENICILLIN G; ROXITHROMYCIN; TELITHROMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BETA HEMOLYTIC STREPTOCOCCUS; CONTROLLED STUDY; HAEMOPHILUS INFLUENZAE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; RESPIRATORY SYSTEM; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; HAEMOPHILUS INFLUENZAE; HUMANS; KETOLIDES; MACROLIDES; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0032852568     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/44.4.445     Document Type: Article

References (19)

1. Chantot, J. F., Gasc, J. C., Gouin d'Ambrieres, S. & Lutz, A. (1983). New ether oxime derivatives of erythromycin A: preparation and antibacterial activities. In Program and Abstracts of the Twenty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract 447, p. 165. American Society for Microbiology, Washington, DC.
2. Chantot, J. F., Bryskier, A. & Gasc, J. C. (1986). Antibacterial activity of roxithromycin: a laboratory evaluation. Journal of Antibiotics 39, 660-8.
3. Fernandes, P. B., Bailer, R., Swanson, R., Hanson, C. W., McDonald, E., Ramer, N. et al. (1986). In-vitro and in-vivo evaluation of A-56268 (TE-031), a new macrolide. Antimicrobial Agents and Chemotherapy 30, 865-73.
4. Retsema, J., Girard, A., Schelkly, W., Manousos, M., Anderson, M., Bright et al. (1987). Spectrum and mode of action of azithromycin (CP-62,993), a new 15 membered ring macrolide with improved potency against Gram-negative organisms. Antimicrobial Agents and Chemotherapy 31, 1939-47.
5. Agouridas, C., Bonnefoy, A. & Chantot, J. C. (1995). In vitro antibacterial activity of RU004, a novel ketolide highly active against respiratory pathogens. Program of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA 1995. Abstract F158, 140. American Society for Microbiology, Washington, DC.
6. Working Party of the British Society for Antimicrobial Chemotherapy. (1991). A Guide to Sensitivity Testing. Journal of Antimicrobial Chemotherapy 27, Suppl. D. 1-50.
7. Holt, H. A., Bywater, M. J. & Reeves, D. S. (1990). In-vitro activity of cefpodoxime against 1834 isolates from domiciliary infections at 20 UK centres. Journal of Antimicrobial Chemotherapy 26, Suppl. E, 7-12.
8. Report of the Comité de l'Antibiogramme de la Société Française de Microbiologie. (1996). Clinical Microbiology and Infection 2, Suppl. 1.
9. Clancy, J., Petitpas, J., Dib-Hajj, F., Yuan, W. Cronan, M., Kamath, A. et al. (1996). Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mefA, from Streptococcus pyogenes. Molecular Microbiology 22, 867-79.
10. Sutcliffe, J., Tait-Kamradt, A. & Wondrack, L. (1996). Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrobial Agents and Chemotherapy 40, 1817-24.
11. Tait-Kamradt, A., Clanc, J., Cronan, M., Dib-Hajj, F., Wondrack, L., Yuan, W. et al. (1997). mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 41, 2251-5.
12. Adrian, F., Gomez-Luz, S., Perez-Trallero, E., Linares, J., Alcaide, F. & Gomez-Luz, R. (1996). Study of MLS-resistance phenotypes in Streptococcus spp. and the genetic basis of this resistance. In Programme and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract C86, p. 50. American Society for Microbiology, Washington, DC.
13. Bryskier, A., Agouridas, C. & Chantot, J. F. (1996). Ketolides: New Semi-synthetic 14 Membered-ring Macrolides in Expanding Indications for the New Macrolides, Azalides and Streptogramins. (Zinner, S. H., Young, L. S., Acar, L. S., Neu, H. C., Eds), pp. 39-50, Marcel Dekker, New York.
14. Agouridas, C., Bonnefoy, A. & Chantot, J. F. (1994). Ketolides, a new distinct semi-synthetic class of macrolides: in vitro and in vivo antibacterial activities. In Program and Abstracts of the Thirty-Fourth Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC.
15. Rosato, A., Vicarini, H., Bonnefoy, A., Chantot, J. F. & Leclercq, R. (1998). A new ketolide, HMR 3004, active against streptococci inducibly resistant to erythromycin. Antimicrobial Agents and Chemotherapy 42, 1392-6.
16. Agouridas, C., Bonnefoy, A. & Chantot, J. F. (1997). Antibacterial activity of RU 64004 (HMR 3004), a novel ketolide derivative active against respiratory pathogens. Antimicrobial Agents and Chemotherapy 41, 2149-58.
17. Barry, A. L., Fuchs, P. C. & Brown, S. D. (1997). In vitro activity of the new ketolide HMR 3004 compared to an azalide and macrolides against Streptococcus pneumoniae and Haemophilus influenzae. European Journal of Clinical Microbiology and Infectious Diseases 16, 767-9.
18. Felmingham, D. & Grüneberg, R. N. (1996). A multi-centre collaborative study of the antimicrobial susceptibility of community-acquired lower respiratory tract pathogens 1992-1998: The Alexander Project. Journal of Antimicrobial Chemotherapy 38, Suppl. A, 1-57.
19. James, P. A., Hossain, F. K., Lewis, D. A. & White, D. G. (1993). β-Lactam susceptibility of Haemophilus influenzae strains showing reduced susceptibility to cefuroxime. Journal of Antimicrobial Chemotherapy 32, 239-46.